152 related articles for article (PubMed ID: 32166993)
1.
Srinivasan A; Zhou Y; Scordino T; Prabhu S; Wierenga A; Simon G; Wierenga KJ; Thompson J; Shah R; Sinha AA
Pediatr Hematol Oncol; 2020 Aug; 37(5):431-437. PubMed ID: 32166993
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing detects somatic mutations of IDH1 in metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria (MC-HGA).
Vissers LE; Fano V; Martinelli D; Campos-Xavier B; Barbuti D; Cho TJ; Dursun A; Kim OH; Lee SH; Timpani G; Nishimura G; Unger S; Sass JO; Veltman JA; Brunner HG; Bonafé L; Dionisi-Vici C; Superti-Furga A
Am J Med Genet A; 2011 Nov; 155A(11):2609-16. PubMed ID: 22025298
[TBL] [Abstract][Full Text] [Related]
3. Novel cases of D-2-hydroxyglutaric aciduria with IDH1 or IDH2 mosaic mutations identified by amplicon deep sequencing.
Nota B; Hamilton EM; Sie D; Ozturk S; van Dooren SJ; Ojeda MR; Jakobs C; Christensen E; Kirk EP; Sykut-Cegielska J; Lund AM; van der Knaap MS; Salomons GS
J Med Genet; 2013 Nov; 50(11):754-9. PubMed ID: 24049096
[TBL] [Abstract][Full Text] [Related]
4. Widespread and debilitating hemangiomas in a patient with enchondromatosis and D-2-hydroxyglutaric aciduria.
Yeetong P; Phewplung T; Kamolvisit W; Suphapeetiporn K; Shotelersuk V
Skeletal Radiol; 2018 Nov; 47(11):1577-1582. PubMed ID: 29744569
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
[TBL] [Abstract][Full Text] [Related]
6. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria.
Kranendijk M; Struys EA; van Schaftingen E; Gibson KM; Kanhai WA; van der Knaap MS; Amiel J; Buist NR; Das AM; de Klerk JB; Feigenbaum AS; Grange DK; Hofstede FC; Holme E; Kirk EP; Korman SH; Morava E; Morris A; Smeitink J; Sukhai RN; Vallance H; Jakobs C; Salomons GS
Science; 2010 Oct; 330(6002):336. PubMed ID: 20847235
[TBL] [Abstract][Full Text] [Related]
7. Computational approach to unravel the impact of missense mutations of proteins (D2HGDH and IDH2) causing D-2-hydroxyglutaric aciduria 2.
Thirumal Kumar D; Jerushah Emerald L; George Priya Doss C; Sneha P; Siva R; Charles Emmanuel Jebaraj W; Zayed H
Metab Brain Dis; 2018 Oct; 33(5):1699-1710. PubMed ID: 29987523
[TBL] [Abstract][Full Text] [Related]
8. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies.
Kranendijk M; Salomons GS; Gibson KM; Van Schaftingen E; Jakobs C; Struys EA
Biochim Biophys Acta; 2011 Nov; 1812(11):1380-4. PubMed ID: 21889589
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndromes and malignant transformation: where the twain shall meet.
Bhagwat N; Levine RL
Sci Transl Med; 2010 Oct; 2(54):54ps50. PubMed ID: 20962328
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.
Rakheja D; Mitui M; Boriack RL; DeBerardinis RJ
Pediatr Blood Cancer; 2011 Mar; 56(3):379-83. PubMed ID: 21225914
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
Elsayed GM; Nassar HR; Zaher A; Elnoshokaty EH; Moneer MM
J Egypt Natl Canc Inst; 2014 Mar; 26(1):43-9. PubMed ID: 24565682
[TBL] [Abstract][Full Text] [Related]
13. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
[TBL] [Abstract][Full Text] [Related]
14. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
Zou Y; Zeng Y; Zhang DF; Zou SH; Cheng YF; Yao YG
Biochem Biophys Res Commun; 2010 Nov; 402(2):378-83. PubMed ID: 20946881
[TBL] [Abstract][Full Text] [Related]
15. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
Birendra KC; DiNardo CD
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
[TBL] [Abstract][Full Text] [Related]
16. IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells.
Matsunaga H; Futakuchi-Tsuchida A; Takahashi M; Ishikawa T; Tsuji M; Ando O
Biochem Biophys Res Commun; 2012 Jul; 423(3):553-6. PubMed ID: 22683334
[TBL] [Abstract][Full Text] [Related]
17. Peripheral neuropathy in a patient with D-2-hydroxyglutaric aciduria.
Haliloglu G; Temucin CM; Oguz KK; Celiker A; Coskun T; Sass JO; Fischer J; Topcu M
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S21-5. PubMed ID: 19169842
[TBL] [Abstract][Full Text] [Related]
18. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.
Gupta C; Kaulfuss S; Görlich K; Othman B; Chaturvedi A; Heuser M
Ann Hematol; 2020 Jun; 99(6):1415-1417. PubMed ID: 32296913
[No Abstract] [Full Text] [Related]
20. D-2-hydroxyglutaric aciduria and glutaric aciduria type 1 in siblings: coincidence, or linked disorders?
Korman SH; Salomons GS; Gutman A; Brooks R; Jakobs C
Neuropediatrics; 2004 Jun; 35(3):151-6. PubMed ID: 15248096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]